Elanco (ELAN)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$23.68-6.44%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · ELAN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 18.8% |
| Our one-year growth estimate | diamond | 6.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Usually moved in the opposite direction.
Price observations: 365 days
Most sensitive to the broad stock market and long-term interest rates.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 12.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 12 industry peers
ELAN — restructuring
Dated 2025-12-09
Costs Associated with Exit or Disposal Activities. On December 5, 2025, the Board of Directors of Elanco Animal Health Incorporated (the “Company”) authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to support margin expansion, optimize the Company’s footprint, and further invest in innovation. The Restructuring Plan will result in a global headcount reduction of approximately 300 employees, plus an approximate 300 employees whose positions will be replac…
Why it matters: Befrena demand was twice the company's prior estimate. More supply could support its launch; short supply could limit sales.
Watch forElanco reports rising weekly supply and more clinics joining the rollout. It has served nearly 1,400 clinics so far.
Also watch forElanco reports supply limits or no further growth beyond the nearly 1,400 clinics served so far.
Why it matters: These products drove much of Pet Health growth. Slower clinic use or market share gains could weaken that growth.
Worry ifThe next report shows lower U.S. JAK share for Zenrelia or lower U.S. clinic share gains for Credelio Quattro than in Q2.
Less concerning ifZenrelia adds to its U.S. JAK share, and Credelio Quattro gains more U.S. clinic share in the next report.
Why it matters: Elanco set Q3 revenue guidance at $1.195 billion to $1.220 billion. A result below the range would weaken its growth outlook.
Worry ifQ3 revenue is below $1.195 billion, or full-year revenue guidance falls below $5.09 billion.
Less concerning ifQ3 revenue is at least $1.195 billion and full-year revenue guidance stays at $5.09 billion or higher.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$135 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $432 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,623 loss on $10,000 · 26.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.